Sparse Data.

Serious Accuracy.

Join Lalin Theverapperuma at PMWC 2026 as he presents Limited Sample Model (LSM), a foundational AI architecture engineered for governance and defensible decisions in regulated science, and examines why scale alone is not enough in AI.

Track 2: AI in Drug Discovery & Computational Biology
March 6 | 2:30–2:45 PM

Limited Sample Model 

A foundational AI architecture engineered to transform sparse data into governed, defensible decisions.

Scientist-Trained. Regulatory-Grade.

Review the Exceptions. 
Not the Whole Batch.

50×

Workflow Capacity
Raw instrument data to signed, LIMS-ready output
across every method and site.

Analyst-Validated,
Production-Proven.

99.9%

Accuracy
Exception-based review with full traceability
eliminates manual decision drift.

Consistent Analysis. 
Run After Run.

7×

Fewer Reruns
One platform across fragmented instruments, software, and data.

Move at the Speed of Discovery. Trust Every Result.

AI has made the front of drug development faster than ever. Validating those candidates hasn't kept up. Analytical decisions are still made by hand and siloed by stage, so the pipeline moves at the speed of its slowest handoff, and the AI tools meant to help can't be trusted in a regulated workflow.

Expert Intelligence weaves those decisions into one analytical fabric across the pipeline. It scales and accelerates every analytical decision with regulatory-grade accuracy, connects them from discovery to manufacturing, and flags risk before it reaches release, scientist-trained, signed, and never hallucinated. Your programs move faster, and every result holds up.

One Platform. Every Instrument.

EI works across your existing instruments, methods, and sites, no rip-and-replace, with standard connectors into your LIMS and enterprise systems. Every result is confidence-calibrated, exception-routed, and regulatory-grade, with full traceability from raw data to signed output.

Your Data Stays Yours

EI deploys into your own environment, cloud, on-premises, or hybrid, so your data never leaves the place it was generated. No new hardware, validated configurations supported, nothing to rip out and replace.

Trained on Your Data. Owned by You.

Your scientists train the model inside your environment, no code required. About 50 examples is enough for it to learn your targets and your decision logic. From there, every analyst correction feeds back through active learning, refining it toward 99.9% accuracy, and the trained model is your institutional IP.

The methods your lab already runs, automated.

EI Flow automates the review across all of them, turning raw instrument data into a SOP-aware, signed, explainable result. Your acceptance criteria, your method, your sign-off, on every one.

HPLC / UPLC

Release, purity, potency, and stability.

EI Flow handles peak review, integration, and specification checks across routine release and stability workflows, automatically clearing conforming results and surfacing new or growing degradants before they reach your queue.

LC-MS / LC-MS/MS / MRM

Bioanalysis, identity, and quantitation.

Run acceptance, quantitation review, metabolite tracking, stability, and impurity monitoring across every injection, with your integration and acceptance decisions applied consistently at every site, including your CROs.

Titer / Potency / Binding Assays

Process, release, and development.

Automated curve fitting and endpoint determination where applicable, with assay acceptance across each method. Out-of-trend potency is flagged while final judgment on higher-variability functional assays stays with your experts.

iCIEF / CE / CE-SDS / SEC

Charge variant, size variant, and aggregation.

Peak identification, integration, and system suitability for biologics release, learning your charge and size calls to clear routine review, and pairing with EI Signal to catch aggregation trends across stability timepoints earlier.

GC-MS / HRMS

Impurity, residual, and identity confirmation.

EI Flow applies your validated acceptance criteria, clears conforming results for the report, and flags out-of-spec findings, closing the detect-to-identify loop with the traceability and consistency regulated workflows demand.

Intact Mass / ADC / AS-MS

Mass confirmation, proteoform, and DAR.

Deconvolution, proteoform analysis, DAR calculation, and microheterogeneity assessment, with consistent, signed interpretation that reads the same from lot to lot.

Glycan Analysis

CMC, comparability, and characterization.

Isomer resolution, ambiguity management, and consistent annotation at scale, monitoring the critical glycan attributes that influence effector function, half-life, and immunogenicity across batches and sites.

Proteomics / Biomarkers / Lipidomics

Mechanism, translational, and clinical evidence.

Protein-, lipid-, and pathway-level confidence through alignment, interference control, and reproducible cross-batch identification, supporting the translational and clinical evidence your programs depend on.

See it in action.

Request a demo and see how trusted results compress the time and cost of drug development.

Book A Meeting